3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
10
Carcinoma, Non-Small-Cell Lung
8
Urinary Bladder Neoplasms
6
Neoplasm Metastasis
6
Prostatic Neoplasms
5
Melanoma
5
Lung Neoplasms
5
Carcinoma, Renal Cell
5
Ovarian Neoplasms
4
Urologic Neoplasms
3
Stomach Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Mesothelioma
2
Hypopharyngeal Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thymus Neoplasms
1
Thymoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Interventions
Gemcitabine
11
pembrolizumab
8
enfortumab vedotin
8
Specimen Handling
8
Cisplatin
8
Magnetic Resonance Spectroscopy
6
avelumab
5
Carboplatin
5
vinflunine
4
Nivolumab
4
atezolizumab
3
Biopsy
3
cabozantinib
2
Standard of Care
2
Ramucirumab
2
Platinum
2
Ipilimumab
2
Immunoglobulin G
2
Doxorubicin
2
Docetaxel
2
Disulfides
2
CTLA-4 Antigen
2
Bortezomib
2
1,2-diaminocyclohexaneplatinum II citrate
2
vandetanib
1
tocilizumab
1
tamibarotene
1
rucaparib
1
relatlimab
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ureteral Neoplasms
×
Pemetrexed
×
Genitourinary
×
Clear all
NCT03193788
2017-06-21
PREMIER
Asan Medical Center
Phase 3
Unknown
74 enrolled